{
    "nctId": "NCT01827787",
    "briefTitle": "Eribulin in HER2 Negative Metastatic BrCa",
    "officialTitle": "A Phase 2 Study of Eribulin in Patients With HER2-Negative, Metastatic Breast Cancer: Evaluation of Efficacy, Toxicity and Patient-Reported Outcomes",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 83,
    "primaryOutcomeMeasure": "Overall Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically proven invasive breast cancer, locally recurrent or metastatic, with at least one measureable lesion according to RECIST v1.1\n* Hormone receptor positive or hormone receptor negative HER2-negative disease\n* Up to one prior line of chemotherapy for advanced disease is allowed (discontinued at least 14 days prior to initiation of protocol therapy)\n* Prior bevacizumab in the neo/adjuvant or metastatic setting is acceptable\n* No limit on prior lines of endocrine therapy, but must be discontinued at least 7 days prior to initiation of protocol therapy\n* Must have completed any prior radiotherapy at least 2 weeks prior to initiation of protocol therapy\n* Must have recovered from reversible effects of prior therapies to no more than grade 1 toxicity, with the exception of alopecia\n* Agree to use adequate contraception for the duration of study participation\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Prior treatment with eribulin\n* Prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer unless diagnosed and definitively treated at least 3 years before enrollment in this study\n* Clinically significant cardiovascular impairment\n* Active brain metastases or unevaluated neurologic symptoms suggestive of brain metastases\n* Pulmonary dysfunction requiring the use of oxygen\n* Prior organ allograft requiring immunosuppression\n* HIV positive on combination antiretroviral therapy\n* Pre-existing grade 3 or 4 neuropathy\n* Hypersensitivity to halichondrin B or halichondrin B chemical derivative\n* Uncontrolled intercurrent illness\n* Inability to read in English",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}